Our Research Results

Since we first began more than 40 years ago, Breast Cancer Trials (BCT) has contributed to more than 1,200 peer-reviewed publications and many of these research results have changed practice in the treatment and prevention of breast cancer.

The publication of the results of clinical trials research in a scientific journal or a periodic publication:

  • Fulfils the researchers’ ethical obligations to research participants and the general community;
  • Contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.

BCT publishes study results in accordance with the BCT Publication Policy.

The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name. 

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as “open access”; however some require a subscription.



Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study.

Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard K, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni & de Azambuja E. British Journal of Cancer. 2022; 1271799 – 1807, Published online 01 September 2022, Journal

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Geyer CE, Garber JE, Gelber RD, Yothers et al. and the OlympiA Clinical Trial Steering Committee and Investigators. Annals of Oncology. 2022; 33(12):1250 – 1268, Journal

Primary results of ANZ 1002: Post-operative Radiotherapy Omission in Selected Patients with Early Breast Cancer Trial.

Rose AK, Skandarajah A, Collin J, Hughes J, Murugasu M, Mou A, Schwartz K, Gebski V, Eggins R, Spillane A, Chua B, Braggett H, Zdenkowski N, Badger H, Mann B. Radiological Society of North America (RSNA) Annual Meeting 2022; Abstract 2022-SP-8728-RSNA, Abstract

Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients.

Miglietta F, Pronzato P, Girardi F, Griguolo G, Guarneri V, Pappagallo G, Conte P, Periplo foundation. European Journal of Cancer. 2022; 175(S1):s57-S58, EBCC-13 Abstract 177/PB-090, Poster

Primary results of ANZ 1002: Post-operative Radiotherapy Omission in Selected Patients with Early breast Cancer Trial (PROSPECT) following pre-operative breast MRI.

Mann B, Rose A, Hughes J, Skandarajah A, Murugasu A, Spillane A, Chua B, Zdenkowski N, Badger H, Braggett H, Gebski V, Eggins R, Park A, Collins J, Breast Cancer Trials. European Journal of Cancer. 2022; 175(S1):S47, EBCC-13 Abstract 149/PB-062, Poster

OPTIMA: a prospective, international, randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy in high clinical risk early breast cancer.

Dunn JA, Kiely BE, Mann B, Makris A, Macpherson IR, Hughes-Davies L, Marshall A, Dotchin G, Cameron DA, Naume B, Hall PS, McIntosh S, Shinkins B, McCabe C, Morgan A, Bartlett JMS, Stein RC, on behalf of the OPTIMA TMG. AIBC 2022; P18, Poster

Total Publications: 1256